CHLOE, CHLOE - instructions for use of the medicine, reviews, description, price

Chloe®

The drug should be taken orally, 1 tablet/day. The tablet is taken without chewing and washed down with a small amount of liquid. It is recommended to take the drug at the same time, preferably after breakfast or dinner.

Chloe® is started on the 1st day of the cycle, using the tablet of the corresponding day of the week from the calendar package. Daily administration of the drug is carried out using tablets from the calendar package sequentially in the direction of the arrow marked on the foil until all the tablets have been taken. After finishing taking all the yellow-orange tablets from the calendar pack, you must take the remaining white tablets over the next 7 days.

During the last 7 days of the treatment cycle (28 days), menstrual-like bleeding should occur (as a result of discontinuation of treatment). Menstruation usually begins 2-3 days after the 21st day of the drug treatment cycle.

The next package must be started the day after the tablets from the previous package are completely taken, regardless of whether bleeding continues/cessation.

When switching from combined oral contraceptives

the use of Chloe® should be started the day after taking the last tablet with the active components of the previous drug, but in no case later than the next day after the usual 7-day break in use (for drugs containing 21 tablets). Continue according to the scheme described above.

If the patient has taken the previous contraceptive daily for 28 days, Chloe® should be started after taking the last inactive tablet.

When switching from contraceptives containing only gestagens (“mini-pills”)

Chloe® can be started without interruption.

When using injectable forms of contraceptives

Chloe® should be used from the day your next injection is due.

When switching from an implant

Chloe should be used on the day of its removal.

In all cases, it is necessary to use an additional barrier method of contraception during the first 7 days of using the drug.

After an abortion in the first trimester of pregnancy

a woman can start using Chloe® immediately. In this case, there is no need for additional methods of contraception.

After childbirth or abortion in the second trimester of pregnancy

Use of the drug should begin on days 21-28. If use is started later, it is necessary to use an additional barrier method of contraception during the first 7 days of using the drug.

If a woman was sexually active between childbirth or abortion and the start of using the drug

, you should first rule out pregnancy or wait until your first menstruation.

Missed pill

should be taken as soon as possible, the next tablet at the usual time.
If the delay is <12 hours,
the reliability of contraception does not decrease.
If the delay in taking the pill is >12 hours
, the reliability of contraception may be reduced.

If the delay in taking pills was >12 hours (the interval since taking the last pill was >36 hours) during the 1st and 2nd weeks

taking the drug, a woman should take the last missed pill as soon as possible, even if this means taking two pills at the same time. The next tablet should be taken at the usual time. Additionally, it is necessary to use a barrier method of contraception for the next 7 days.

If the delay in taking the tablet was >12 hours (the interval since the last tablet was taken >36 hours) during the 3rd week

taking the drug, a woman should take the last missed pill as soon as possible, even if this means taking two pills at the same time. The next tablet should be taken at the usual time. Taking tablets from a new package should be started without interruption at the end of the current package. There will probably be no withdrawal bleeding until the end of the second pack, but spotting or breakthrough uterine bleeding is possible on the days of taking the pills.

If a woman has vomited within 3 to 4 hours after taking the drug, absorption of the active substances may be incomplete. In this case, you need to follow the recommendations when skipping a pill.

To delay the start date of menstruation,

a woman should continue taking tablets from a new package of the drug immediately after taking all the tablets from the previous one, without interruption. Tablets from the new package can be taken for as long as the woman wishes (until the package runs out). While taking the drug from the second package, a woman may experience spotting or breakthrough uterine bleeding. You should start taking the tablets from the next pack after you have completed taking all 28 tablets.

To move the start date of your period to another day of the week,

a woman should shorten her next break from taking pills by as many days as she wants. The shorter the interval, the higher the risk that she will not have withdrawal bleeding and, in the future, will have spotting and breakthrough bleeding while taking the second package (the same as in the case when she would like to delay the onset of menstruation).

In the treatment of hyperandrogenic conditions

The duration of use of the drug is determined by the severity of the disease. After the symptoms disappear, it is recommended to take the drug for at least 3-4 months. If a relapse occurs several weeks or months after completion of the course, re-therapy with Chloe® can be performed.

Chloe - instructions, composition, dosage, side effects of use

Chloe

Chloe _

Read also: Complivit® for women 45 plus

Main physical and chemical characteristics : yellow-orange, wallpaper-convex, film-coated tablets; placebo: white wallpaper convex tablets;

Compound. 1 film-coated tablet contains cyproterone acetate 2 mg, ethinyl estradiol 0.035 mg;

other components: lactose monohydrate, povidone, sodium carboxymethyl starch (type A), colloidal silicon dioxide anhydrous, colloidal aluminum oxide, magnesium stearate, Opadry II OY-L-32901 yellow (lactose monohydrate, hypromelose 2910/15, titanium dioxide, macrogol 4,000 , iron oxide yellow, iron oxide black, iron oxide red);

placebo tablet: lactose monohydrate, povidone, sodium carboxymethyl starch (type A), colloidal silicon dioxide anhydrous, colloidal aluminum oxide, magnesium stearate.

Release form of the medicine. Film-coated tablets.

Pharmacotherapeutic group. Antiandrogens. ATC code G03HB01.

Action of the medicine . Pharmacodynamics. The active substances contained in the drug "Chloe", cyproterone acetate, inhibits the effect of androgens that are formed in a woman's body. With the help of this substance, it is possible to treat diseases caused by increased synthesis of androgens, or diseases caused by increased sensitivity to these hormones.

While taking Chloe, the enhanced function of the sebaceous glands, which play an important role in the development of acne and seborrhea, is inhibited. This usually leads to the disappearance of the existing rash within 3 to 4 months of treatment. Previously, excessive oiliness of the skin and hair usually disappears. As a rule, hair loss, which often accompanies seborrhea, decreases or disappears. Chloe's treatment is indicated for women of reproductive age who exhibit moderate forms of hirsutism, especially slightly increased facial hair. However, results do not become obvious until after several months of treatment.

In addition to the antiandrogenic effect, cyproterone acetate also has a pronounced gestagenic effect. For this reason, taking cyproterone acetate alone can lead to cycle disruption, which can be avoided by combining it with ethinyl estradiol, as is the case in Chloe. This combination is effective if the drug is taken cyclically according to the instructions given below.

Chloe's contraceptive effect is based on the compatible activity of various factors, the most important of which is inhibition of ovulation and changes in cervical excretion. In addition to protection against pregnancy, the combination of estrogen/progestagen versus antiandrogen provides additional benefits that may be helpful in deciding whether or not to use a given method of contraception. The cycle becomes more regular, menstruation becomes less painful, and menstrual bleeding is lighter. Thanks to this, the incidence of iron deficiency anemia can be reduced. There is evidence that the use of high doses of combined oral contraceptives (0.05 mg ethinyl estradiol) has been shown to reduce the risk of developing ovarian cysts, pelvic inflammatory disease, benign breast tumors and ectopic pregnancy. It remains to be confirmed whether low-dose combined oral contraceptives have the same effect.

Pharmacokinetics.

Cyproterone acetate

After oral use, cyproterone acetate is absorbed quickly and completely. Peak serum concentrations of 15 ng/mL are achieved approximately 1.6 hours after administration. Bioavailability is 88%.

Cyproterone acetate binds almost exclusively exclusively to plasma albumin. Approximately 3.5 – 4% of the total serum concentration is present in free form. Ethinyl estradiol, an induced increase in the level of globulin that binds to the sex hormone, does not show any effect on the protein binding of cyproterone acetate. The volume of distribution of cyproterone acetate is 986 ± 437 l.

Cyproterone acetate is metabolized almost completely. The main metabolite in plasma is identified as a 15β-hydroxy derivative and is formed by the cytochrome P450 enzyme CYP3A4. Serum clearance for cyproterone acetate is 3.6 ml/minute. /kg.

The serum level of cyproterone acetate decreases in two stages of elimination, which are characterized by a half-life of 0.8 hours and 2.3 - 3.3 days. Cyproterone acetate is partially excreted unchanged. Its metabolites are excreted in urine and bile in a 1:2 ratio. The half-life of metabolites is approximately 1.8 days.

The pharmacokinetics of cyproterone acetate is not affected by levels of globulin, which binds the sex hormone. After daily dosing of the drug, its level increases approximately 2.5 times, and in the second part of the therapeutic cycle a stable state is achieved.

Ethinyl estradiol

After oral use, ethinyl estradiol is absorbed quickly and completely. The maximum serum concentration is approximately 71 pg/ml and is achieved within 1.6 hours. During absorption and during the first pass through the liver, ethinyl estradiol is extensively metabolized, resulting in an average oral bioavailability of approximately 45% and up to a significant interindividual variability of approximately 20 – 65%.

Ethinyl estradiol actively, but nonspecifically binds to serum albumin (approximately 98%) and induces an increase in serum concentrations of globulin, which binds the sex hormone. The volume of distribution is approximately 2.8 – 8.6 l/kg.

Ethinyl estradiol is subject to systemic conjugation both in the wall of the small intestine and in the liver. Ethinyl estradiol is primarily metabolized through aromatic hydroxylation, however a large number of different hydroxylated and methylated metabolites are synthesized and these metabolites are present in free form or conjugated to glucuronic and sulfuric acid. Metabolic clearance is established as 2.3 - 7 ml/minutes. /kg.

Ethinyl estradiol levels decrease in two pharmacokinetic steps with half-lives of approximately 1 hour. and 10 - 20 hours. Unchanged ethinyl estradiol is not excreted; its metabolite is excreted in urine and bile in a ratio of 4:6. The half-life of metabolites is approximately 1 day.

Steady state is achieved in the second part of the therapeutic cycle, with serum levels 60% higher than the individual dose.

Indications for use . Treatment of androgen-dependent diseases in women, such as acne, especially severe forms, and those accompanied by seborrhea, inflammation or nodule formation (papular-pustular acne, nodular-cystic acne); androgenetic alopecia; mild forms of hirsutism. It can be used as a contraceptive (however, the drug cannot be used solely for the purpose of contraception, but should be prescribed to women for the treatment of androgen-dependent conditions).

Method of use and dose. To achieve a therapeutic effect and the necessary contraceptive protection, Chloe should be used regularly. The dosage regimen of the drug is the same as for most combined oral contraceptives. It is recommended to use Chloe for at least 3 to 4 menstrual cycles after the symptoms disappear. If symptoms recur, Chloe's treatment can be repeated a few weeks or months after treatment ends.

The tablets should be taken in the indicated sequence daily and at approximately the same time. If necessary, tablets can be taken with water. You should take 1 tablet per day for 28 days. Tablets from a new package should be taken after a seven-day interval for taking placebo tablets, during which menstrual bleeding as a result of drug withdrawal occurs approximately 2 to 3 days after the last dose of the active tablet. When starting to use a new pack, a woman may still experience menstrual bleeding.

In the absence of prior use of hormonal contraceptives (in the previous month)

Taking the pills begins on the first day of a woman’s natural menstrual cycle (that is, on the first day of menstrual bleeding). You can also start taking it on days 2–5, however, it is recommended to additionally use a barrier method of contraception during the first 7 days of the first menstrual cycle.

Switching from another combined oral contraceptive (COC)

Fenoprofen calcium - instructions, composition, dosage, side effects of use

The best time to start using Chloe is immediately the day after the last active pill of the oral contraceptive the woman was taking previously, but no later than the day after the usual pill-free interval, or after the placebo pill period of the pre-contraceptive pill.

Switching from a method that is based on the use of progestogen only (mini-pills, injections, implants), or from intrauterine progestogen release (IUD)

The transition from the “mini-pill” is possible at any hour (from an implant or IUD - on the day they are discontinued, from injections - on the day when the next injection is due), however, in all these cases it is recommended to use a barrier method of contraception for the first 7 days of taking the pills.

Use after abortion in the first trimester

In such cases, the woman can start taking it immediately. In this case, there is no need for the following contraceptives.

Use after childbirth or abortion in another trimester

It is recommended that a woman start taking the pills between 21 and 28 days after giving birth or having an abortion in another trimester. If a woman starts taking the pills later, she is recommended to additionally use a barrier method of contraception during the first 7 days of using the pills. However, if sexual intercourse has taken place in the meantime, a possible pregnancy should be excluded or the woman should wait until her first menstrual bleeding occurs.

If less than 12 hours have passed since you missed a pill, this will not affect contraceptive protection. The woman should take the pill as soon as she remembers it, and the next pill should be taken on the regular schedule.

If the delay in taking the pill is more than 12 hours, contraceptive protection may decrease. In this case, the following measures may include two basic rules:

1) You should never stop taking pills for more than 7 days.

2) To achieve appropriate inhibition of the activity of the hypothalamic-pituitary-ovarian system, a 7-day period of continuous pill taking is required.

In accordance with the above rules, you can date such recommendations:

1st week

A woman should take the last missed pill as soon as she remembers, even if she has to take 2 pills at the same time. After this, the tablets should be taken at the usual time. Additionally, you should use a barrier method of contraception for the next 7 days, such as a condom. If sexual intercourse has taken place within the previous 7 days, the possibility of pregnancy should be considered. The greater the number of missed tablets and the closer in time to the usual interval of taking placebo tablets, the higher the risk of pregnancy.

2nd week

A woman should take the last missed pill as soon as she remembers, even if she has to take 2 pills at the same time. After this, the tablets should be taken at the usual time. If a woman has taken the pills regularly for 7 days before the first missed pill, there is no need for further contraceptive visits. And if not, or if a woman has missed more than 1 tablet, it is recommended to carry out special contraceptive measures for 7 days.

3rd week

After the next interval of taking placebo pills, there is a risk of reducing the reliability of contraception. However, despite this fact, if you adjust the dosage schedule, you can prevent a decrease in contraceptive protection. If a woman adheres to one of the two possible procedures listed below, there is no need for other contraceptive visits if the woman took the pills correctly in the period 7 days before missing the first pill. Otherwise, the woman must use the first two options listed below, and use additional contraceptive measures for 7 days:

1) A woman should take the last missed pill as soon as she remembers, although this means taking 2 pills at the same time. After this, she should continue to take the pills on her regular schedule. In this case, the next package should be started immediately after taking all active tablets from the previous package; therefore, taking placebo tablets should be skipped. Menstrual bleeding, associated with drug withdrawal, will probably occur only after completely taking all the tablets from the other package, however, while taking these tablets, spotting (“mazanina”) or sudden bleeding is possible.

2) The woman may also be advised to start taking the placebo tablet with the first pack. This will achieve a 7-day interval without taking active tablets, including days when active tablets were missed, and then active tablets should be started with the next pack.

If a woman forgets to take a pill and then does not experience bleeding during the first regular pill-free interval due to drug withdrawal, the possibility of pregnancy should be considered.

4th week

The tablets are intended to be taken for 4 weeks and contain no active ingredients. Therefore, if taking active pills from the next cycle began on the next day, errors in taking these pills can be neglected.

Recommendations in case of gastrointestinal disorders

In case of severe gastrointestinal disorders, the absorption of tablets may be difficult and then other contraceptive measures are necessary.

If vomiting occurs within 3 to 4 hours after taking the pill, you can use the procedure that is recommended in case of missing a pill. If a woman does not want to change her usual pill-taking schedule, she should take an additional pill(s) from a different pack.

How to change the hour of menstruation or delay menstruation

If a woman wishes to prevent menstrual bleeding, she should continue to take the active tablets from another pack of Chloe without taking the placebo tablets. Thus, you can continue taking the active tablets until you have completely taken all the active tablets from the other pack. During this time, sudden bleeding or bleeding may occur. After the 7-day placebo tablet interval, the woman should continue taking Chloe regularly again.

If a woman wishes to reschedule her period on a different day of the week than her usual schedule, she may be advised to shorten the initial interval for taking placebo tablets and take them for as many days as she wishes. The shorter this interval, the higher the risk that menstrual bleeding will not occur due to drug withdrawal, but sudden bleeding and spotting will occur during the next package (the same as in the case of delayed menstruation).

Duration of treatment

The duration of treatment depends on the severity of the disease. Treatment should usually continue for several months.

Side effect. The most serious adverse reactions associated with taking combined oral contraceptives (COCs), listed in the section “Peculiarities of use”.

Other adverse reactions that have been reported with the use of COCs (however, their connection with COCs has not been confirmed or refuted):

— mammary glands: tension, pain, enlargement, discharge from the nipples;

- disorders of the central nervous system: headache, migraine, libido, depressed mood, mood swings;

- disorders of the gastrointestinal system: nausea, vomiting or other digestive disorders;

- various skin manifestations: rashes, erythema nodosum;

- disorders of the skin and subcutaneous tissues: exudative erythema multiforme;

— disorders of the reproductive system: changes in vaginal secretion;

Ideos - instructions, composition, dosage, side effects of use

— ophthalmological disorders: intolerance to contact lenses;

- abnormal clinical manifestations: fluid retention, changes in body weight, hypersensitivity reactions.

Restrictions and contraindications in the use of the drug. Preparations that contain a combination of estrogen/progestogen cannot be used if a woman has been diagnosed with at least one of the following conditions:

the presence of venous or arterial thrombotic/thromboembolic processes (for example, deep venous thrombosis, pulmonary embolism, myocardial infarction) or confirmation of a history of cerebrovascular episodes of such conditions;

a history of prodromes of thrombosis (for example, transient ischemic disorder, angina pectoris);

migraine with a history of focal neurological symptoms;

diabetes mellitus with vascular damage;

severe or multiple risk factors for the development of venous or arterial thrombosis may also be contraindications;

pancreatitis or a history of this disease, if it was associated with hypertriglyceridemia;

serious liver diseases - current or in history - until liver function values return to normal;

there are liver tumors or a history of them (benign or malignant);

the presence of sex steroid-dependent malignant tumors (genital organs or mammary gland) or suspicion of such;

vaginal bleeding with undiagnosed causes;

pregnancy is known or suspected;

lactation;

hypersensitivity to the active ingredients or to any neutral excipients of the drug.

If these conditions appear at first, treatment should be stopped immediately.

The drug "Chloe" is not prescribed for the treatment of men.

Exceeding the permissible dose of the drug (overdose). There is no information about serious negative effects in overdose. Symptoms that may occur include nausea, vomiting, and in young girls, slight vaginal bleeding. There are no antidotes, and subsequent treatment should be symptomatic.

Features of use. Warnings

If some of the above risk factors are present, the benefits of using Chloe must be weighed against the potential risks associated with using this drug for each individual woman, and these risks should be discussed with the woman before she decides to use the drug. When registering a deepening or the first manifestations of some of the above conditions, the woman should consult a doctor to resolve the issue, or cancel Chloe.

Pregnancy and lactation

Chloe is contraindicated during pregnancy. If a woman becomes pregnant while taking the drug, the drug should be stopped immediately.

The drug is also contraindicated during lactation.

Circulatory disorders

Epidemiological studies indicate an association between the use of combined oral contraceptives and an increased risk of arterial and venous thrombosis and thromboembolic diseases, such as myocardial infarction, cerebrovascular episode, deep venous thrombosis and pulmonary embolism. These episodes are very rare.

During the use of any combined oral contraceptive, venous thromboembolism (VTE), which manifests itself as deep venous thrombosis and/or pulmonary embolism, may occur. The estimated incidence of VTE in women who take oral contraceptives with low doses of estrogens (less than 0.05 mg ethinyl estradiol) is up to 4 per 10,000 women/hour, compared with 0.5 to 3 per 10,000 women/hour among women who do not take oral contraceptives. The incidence of pregnancy-associated VTE is 6 per 10,000 pregnant women/hour.

Very rarely, thrombosis localized in other blood vessels, for example, hepatic, mesenteric, renal, cerebral or retinal veins and arteries, was recorded in women who took combined oral contraceptives. There is no consensus on whether these episodes are actually caused by taking combined oral contraceptives.

Signs of venous or arterial thrombotic/thrombolytic episodes or cerebrovascular episodes may include: unilateral leg pain and/or swelling, sudden severe chest pain that may radiate to the left arm, sudden apnea, sudden coughing attack, any unusual severe or prolonged headache, sudden complete or partial loss of vision, diplopia, unclear speech or aphasia, vertigo, collapse with or without focal symptoms, weakness or severe paralysis that immediately affects half or part of the body, motor disturbances, “acute” life.

The risk of venous or arterial thrombotic/thromboembolic episodes or the risk of a cerebrovascular episode increases:

age;

tobacco smoking (active smoking in old age further increases the risk, which is especially typical for women over 35 years of age);

positive family history (eg, venous or arterial thromboembolism in siblings or parents at a relatively young age). If there is a suspicion of a hereditary tendency, the woman should be examined by a specialist before a decision is made about taking combined oral contraceptives;

excessive weight (body mass index more than 30 kg/m2);

dislipoproteinemia;

arterial hypertension;

migraine;

heart valve disorders;

atrial fibrillation;

long-term immobilization, extensive surgery, any surgery on the legs, more serious lesions. In such cases, it is acceptable to stop taking combined oral contraceptives (in the case of elective surgery, at least four weeks in advance) and start again only two weeks after complete remobilization.

There is no consensus regarding the potential role of varicose veins and superficial thrombophlebitis in the development of venous thromboembolism.

Attention should be paid to the increased risk of thromboembolism during the postpartum period.

Other diseases that are associated with adverse circulatory effects include diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis), and sickle cell anemia.

Increased frequency or severity of migraine while taking combined oral contraceptives (this may include the prodrome of a cerebrovascular episode) may be a reason for immediate discontinuation of combined oral contraceptives.

Biochemical factors that may indicate a hereditary or acquired susceptibility to venous or arterial thrombosis include activated protein C (APC) resistance, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) .

When weighing the risk/benefit comparison, the physician should take into account that appropriate treatment of these conditions may reduce the risk of thrombosis, and that the risk associated with pregnancy is greater than the risk with low dose (<0.05 mg ethinyl estradiol) combined oral contraceptives.

Tumors

Following some epidemiological studies of long-term use of combined oral contraceptives, there have been reports of an increased risk of cervical carcinoma. However, until this time, there is ongoing debate about the extent to which this result may be associated with sexual behavior and other factors, such as human papillomavirus (HPV).

A meta-analysis of 54 epidemiological studies indicates a nonsignificantly increased relative risk (RR = 1.24) of breast carcinoma diagnoses in women who simply took COCs. This increased risk gradually decreases over 10 years after stopping COC use. Due to the fact that breast carcinoma rarely occurs in women under 40 years of age, the increase in the incidence of breast carcinoma diagnosed in current and previous COC users is low in relation to the overall risk of breast carcinoma. These studies do not provide any evidence of causation. The increased risk of breast carcinoma observed in COC users may be due to early diagnosis, a biological effect of the COC, or a combination of these two factors. Breast carcinoma that is diagnosed in current or previous users is usually clinically less severe than in those who have never used the PDA.

Rederm description and instructions for use of the drug.

Rarely, women who take COCs have been diagnosed with benign liver tumors, and malignant liver tumors have been even rarer. Such tumors rarely caused intra-abdominal bleeding, which became a threat to life. If a woman who is taking COCs experiences severe pain in the epigastric zone, an enlarged liver, or signs of intra-abdominal bleeding, different diagnoses should be weighed against the possibility of a liver tumor.

Other states

Women who suffer from hypertriglyceridemia or have a family history of this disease may have an increased risk of pancreatitis while taking combined oral contraceptives (COCs).

Despite the fact that many women who took COCs experienced a slight increase in blood pressure, clinically significant increases are rare. However, if clinically significant hypertension develops while taking a COC, the physician should be cautious, discontinue the combined oral contraceptive pill, and correct the hypertension. As soon as normal blood pressure values are achieved through antihypertensive therapy, if the doctor decides positively, COC therapy can be resumed again.

Both in connection with pregnancy and in connection with taking COCs, they talk about deepening the first manifestations of such conditions, but the evidence of a connection with COCs is not convincing: jaundice and/or pruritis associated with cholestasis, formation of gallstones, porphyria, systemic lupus erythematosus, hemolytic-uremic syndrome, Sydenham's chorea, herpes of pregnancy, hearing loss due to otosclerosis.

Cancellation of COCs may be non-negotiable for acute or chronic disorders of hepatic function during the period until markers of hepatic function return to normal. Discontinuation of COC treatment is also necessary in case of relapse of cholestatic jaundice, which occurs for the first time during pregnancy or during prior use of sex steroids.

Despite the fact that COCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence that changes in diabetes treatment regimen are necessary in diabetic women taking low doses of COCs (less than 0.05 mg ethinyl estradiol). In any case, women with diabetes who take COCs should be closely monitored.

Crohn's disease and ulcerative colitis may be associated with COC use.

Chloasma is sometimes recorded, especially in women who have a history of chloasma during pregnancy. Women who are prone to developing chloasma while taking COCs should avoid sun exposure and exposure to ultraviolet rays.

If in women who suffer from hirsutism, symptoms have recently appeared or have become significantly worse, its cause should be diagnosed differently (androgen-producing tumor, enzyme defect of the adrenal glands).

Medical examination

Before starting or renewing use of combined oral contraceptives (COCs), it is necessary to obtain a complete medical history for the woman and conduct a medical examination including an examination of contraindications and warnings. Viewing should be repeated regularly. Regular medical examination is important since contraindications (for example, transient ischemic conditions) or risk factors (for example, a family history of venous or arterial thrombosis) may first appear only while taking the COC. The frequency and nature of these examinations should be based on well-established practice procedures and be individualized, but in general they should include examination of blood pressure, breast, abdominal and pelvic organs, including cervical cytology.

Women should be made aware of the fact that oral contraceptives do not protect them from HIV infection (AIDS) and other sexually transmitted diseases.

Reduced efficiency

The effectiveness of Chloe may be reduced, for example, when a pill is missed, in the case of gastrointestinal disorders, or when taking other medications at the same time.

Poor menstrual cycle control

When taking drugs based on a combination of estrogen/progestagen in relation to an antiandrogen, there have been reports of irregular bleeding (spotting or sudden bleeding), mainly during the first months of use. For this reason, it is reasonable to look for the cause of irregular bleeding only after an adaptation period of approximately three cycles.

If irregular bleeding continues or if it occurs after a period of regular cycles, then it is necessary to consider the possibility of a non-hormonal cause and carry out appropriate diagnostic procedures to exclude malignancy or pregnancy. Curettage may also be necessary.

Some women may not experience bleeding while taking placebo tablets due to drug withdrawal. If COCs are taken as directed, pregnancy is not possible. However, if the COC was not taken regularly before the first absence of bleeding or bleeding associated with withdrawal did not occur twice, then the possibility of pregnancy should be excluded before further use of the COC.

Interaction with other drugs. Interactions between drugs that include a combination of estrogen/progestogen in relation to antiandrogen and other drugs may lead to bleeding through penetration and/or failure of contraception.

There have been reports in the literature about the following types of interactions:

Hepatic metabolism. There may be an interaction with drugs that induce microsomal enzymes, which can lead to increased clearance of sex hormones (for example, with phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and apparently also with oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin and preparations containing St. John's wort).

Interaction with the intrahepatic blood flow. Some clinical studies describe a decrease in intrahepatic estrogen circulation with the use of certain antibiotics (eg, penicillins, tetracyclines), which may reduce ethinyl estradiol concentrations.

Women who are treated with some of these drugs should, in addition to Chloe, briefly use a barrier method of contraception or reverse another method of contraception. When taking drugs that induce microsomal enzymes, the barrier method should be used during treatment with this drug and for the next 28 days after discontinuation of its active components. Women taking antibiotics (except rifampicin and griseofulvin) should use the barrier method for an additional 7 days after finishing treatment. If treatment is delayed by the end of the active Chloe tablets from the current pack, then the next pack should be started without the usual interval of taking placebo tablets.

The combination of estrogen/progestogen in relation to the antiandrogen contained in Chloe may affect the metabolism of other drugs. Thus, plasma and tissue concentrations (for example, cyclosporine) may be affected.

Caution: Specific information regarding accompanying therapy should be referred to for potential interactions.

Laboratory examination

The use of contraceptive steroids may affect the results of some laboratory tests, including biochemical parameters of hepatic, thyroid, adrenal and renal functions, plasma levels of proteins (to which the drug binds), such as corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism, and parameters of coagulation fibrinolysis . However, shifts typically remain within normal laboratory test values.

Features of conditions, storage and sales periods. . Keep in original packaging, out of the reach of children, at temperatures up to 25 °C.

Shelf life – 3 years.

Chloe, 2 mg+35 mcg, film-coated tablets, 84 pcs.

Before starting to use the drug CHLOE®, it is necessary to conduct a general medical examination (including mammary glands and cytological examination of the cervical epithelium), exclude pregnancy and disorders of the blood coagulation system. With long-term use of the drug, preventive control examinations must be carried out every 6 months.

If there are risk factors, the potential risks and expected benefits of therapy should be carefully assessed and discussed with the woman before she decides to start taking the drug.

If any of these conditions or risk factors worsen, intensify, or appear for the first time, discontinuation of the drug may be necessary.

The use of the drug CHLOE® leads to an increased risk of developing VTE compared to the risk in women not taking the drug.

The additional risk of VTE is greatest during the first year of use of CHLOE® or when use is resumed after a break of 4 weeks or more. VTE can be fatal in 1–2% of cases. The estimated incidence of VTE with low-dose estrogen COCs (less than 50 mcg ethinyl estradiol) is up to 4 cases per 10,000 women per year, compared with 0.5 to 1 per 10,000 women not taking COCs. However, the incidence of VTE when taking COCs is less than the incidence of VTE associated with pregnancy (6 cases per 10,000 pregnant women per year).

Epidemiological studies have shown that the incidence of VTE is 1.5 to 2 times higher in women taking CHLOE® compared to COCs containing levonorgestrel, and similar for COCs containing desogestrel/gestodene/drospirenone.

Patients with polycystic ovary syndrome have an increased risk of developing cardiovascular disease.

Epidemiological studies have also shown an association between the use of hormonal contraceptives and an increased risk of arterial thromboembolism (myocardial infarction, transient ischemic attacks).

Thrombosis of other vessels, namely the veins and arteries of the liver, mesentery, kidney, brain or retina, has been extremely rarely reported in persons taking hormonal contraceptives.

The patient should be warned that if symptoms of venous or arterial thrombosis develop, she should immediately consult a doctor. These symptoms include unilateral lower extremity pain and/or swelling; sudden severe chest pain radiating to the left arm or without radiating; sudden shortness of breath; sudden attack of coughing; any unusual, severe, prolonged headache; increased frequency and severity of migraines; sudden partial or complete loss of vision; diplopia; slurred speech or aphasia; dizziness; collapse with/or without partial seizure; weakness or significant loss of sensation that suddenly appears on one side or in one part of the body; movement disorders; acute stomach

The risk of VTE increases:

- with increasing age;

- when smoking (with heavy smoking and with increasing age, the risk further increases, especially in women over 35 years of age. Women over 35 years of age should be strongly advised to stop smoking if they want to take CHLOE®);

- with a burdened family history (i.e., with a history of cases of VTE at a relatively young age in parents or close relatives). If a hereditary predisposition is suspected, the woman should consult a specialist before deciding on any hormonal contraception;

- with prolonged immobilization, surgical interventions on the lower extremities, neurosurgical operations or extensive trauma. In these situations, it is necessary to discontinue use (in the case of a planned operation, at least 4 weeks in advance), and not resume it until 2 weeks have passed after complete restoration of motor activity. If CHLOE® has not been discontinued in advance, antithrombotic therapy should be considered;

- for obesity (body mass index more than 30 kg/m2).

The risk of arterial thromboembolic complications or cerebrovascular accident increases:

- with increasing age;

- with dislipoproteinemia;

- for arterial hypertension;

- for migraine;

- for diseases of the heart valves;

- with atrial fibrillation;

- with a burdened family history (i.e., if there is a history of cases of arterial thrombosis at a relatively young age in parents or close relatives). If a hereditary predisposition is suspected, a woman should consult a specialist before deciding on any hormonal contraception.

Peripheral circulatory disorders may also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (namely Crohn's disease or ulcerative colitis) and sickle cell anemia.

The increased risk of thromboembolism in the postpartum period must be taken into account.

An increase in the frequency or severity of migraine attacks while using the drug CHLOE® (which may be a harbinger of cerebrovascular accident) is grounds for immediate discontinuation of the drug.

There is no consensus regarding the potential role of varicose veins and superficial thrombophlebitis in the development of VTE.

Biochemical factors that may indicate hereditary or acquired predisposition to venous or arterial thrombosis include APS resistance, hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

When assessing the risk/benefit ratio, the physician should take into account that appropriate treatment of the underlying pathology may reduce the risk of thrombosis. Women taking CHLOE® should be advised of the need to promptly report to their doctor if possible symptoms of thrombosis develop. In case of thrombosis or suspicion of its occurrence, treatment with CHLOE® should be discontinued. Considering the teratogenicity of anticoagulants (coumarins), the use of adequate methods of contraception should be started.

Other states

In women with hypertriglyceridemia, while taking COCs (if there is a family history of this condition), there may be an increased risk of developing pancreatitis. The relationship between taking COCs and arterial hypertension has not been established. If persistent arterial hypertension occurs, CHLOE® should be discontinued and appropriate antihypertensive therapy should be prescribed. Taking the contraceptive can be continued if blood pressure normalizes.

If liver dysfunction occurs, temporary discontinuation of the drug CHLOE® may be required until laboratory parameters normalize.

Recurrent cholestatic jaundice, which develops for the first time during pregnancy or previous use of sex hormones, requires discontinuation of COC use.

Although COCs have an effect on insulin resistance and glucose tolerance, there is usually no need to adjust the dose of hypoglycemic drugs in patients with diabetes mellitus. However, this category of patients should be under close medical supervision.

Women with a tendency to chloasma should avoid prolonged exposure to the sun and exposure to UV radiation while taking COCs.

If symptoms have recently developed or become significantly worse in women with hirsutism, other causes, such as androgen-producing tumor, congenital adrenal dysfunction, should be considered in the differential diagnosis.

While taking CHLOE®, irregular bleeding (spotting or breakthrough bleeding) may sometimes occur, especially during the first months of therapy. Therefore, any irregular bleeding should be assessed only after an adaptation period of approximately 3 cycles.

In some cases, withdrawal bleeding may not develop during a break from taking the pills. If you do not take the pills regularly or in the absence of two menstrual-like bleeding in a row, pregnancy should be excluded before continuing to take the drug.

It is possible that the results of skin allergy tests may change and the concentrations of LH and FSH may decrease. Due to the fact that the contraceptive effect is fully manifested by the 7th day from the start of taking the drug, additional non-hormonal methods of contraception are recommended in the first week.

It is recommended to prescribe the drug after childbirth in the absence of breastfeeding only after the completion of the first normal menstrual cycle.

Treatment must be stopped 3 months before the planned pregnancy.

With diarrhea and vomiting, the contraceptive effect is reduced (without stopping the drug, it is necessary to use additional non-hormonal methods of contraception).

Tumors

There are reports of a slight increase in the risk of developing cervical cancer with long-term use of COCs. The connection with taking COCs has not been proven. It remains controversial to what extent these findings are associated with cervical pathology or characteristics of sexual behavior (less frequent use of barrier methods of contraception).

The most significant risk factor for developing cervical cancer is persistent human papillomavirus infection. A meta-analysis of 54 epidemiological studies showed that there is a slightly increased relative risk of developing breast cancer diagnosed in women currently taking COCs (relative risk 1.24). The increased risk gradually disappears within 10 years of stopping these drugs. Because breast cancer is rare in women under 40 years of age, the increase in breast cancer diagnoses in current or recent COC users is small relative to the overall risk of breast cancer. Its connection with COC use has not been proven. The observed increased risk may also be a consequence of earlier diagnosis of breast cancer in women using COCs. Women who have ever used COCs are diagnosed with earlier stages of breast cancer than women who have never used them.

In rare cases, the development of liver tumors has been observed during the use of COCs, which in some cases led to life-threatening intra-abdominal bleeding. This should be taken into account when making a differential diagnosis in the event of severe abdominal pain, liver enlargement, or signs of intra-abdominal bleeding.

Laboratory tests

The use of COCs may affect the results of laboratory tests, including biochemical indicators of the efficiency of the liver, thyroid gland, adrenal glands and kidneys, the concentration of blood plasma proteins, such as DRGs, as well as the lipid / lipoprotein composition of the blood, indicators of carbohydrate metabolism and blood coagulation system. However, deviations usually remain within the range of normal laboratory values.

Chloe

Use during pregnancy and breastfeeding

The use of the drug is contraindicated during pregnancy, suspected pregnancy and during breastfeeding.

Use for liver dysfunction

The use of the drug is contraindicated for diseases or severe liver dysfunction, liver tumors (including a history), congenital hyperbilirubinemia (Gilbert, Dubin-Johnson, Rotor syndromes), idiopathic jaundice or itching during the last pregnancy.

The drug should be used with caution for diseases of the liver and gallbladder.

Use for renal impairment

The drug should be used with caution in case of kidney disease.

Use in elderly patients

Contraindicated over the age of 40 years.

special instructions

Before starting to use Chloe®, it is necessary to conduct a general medical examination (including mammary glands and cytological examination of cervical mucus), exclude pregnancy and disorders of the blood coagulation system. With long-term use of the drug, preventive control examinations must be carried out every 6 months.

If there are risk factors, the potential risk and expected benefit of therapy should be carefully assessed and discussed with the woman before starting the drug.

If the severity, intensification, or first manifestation of any of the following conditions or risk factors increases, discontinuation of the drug may be necessary.

The use of Chloe® leads to an increased risk of developing venous thromboembolism (VTE) compared with the risk in women not taking the drug. The additional risk of VTE is greatest during the first year of use of Chloe® or when use is resumed after a break of 4 weeks or more. VTE can be fatal in 1-2% of cases. The estimated incidence of VTE when taking oral contraceptives with low doses of estrogens (less than 50 mcg ethinyl estradiol) is up to 4 per 10,000 women per year, compared with 0.5-1 per 10,000 women not taking COCs. However, the incidence of VTE when taking COCs is less than the incidence of VTE associated with pregnancy (6 per 10,000 pregnant women per year).

Epidemiological studies have shown that the incidence of VTE is 1.5 to 2 times higher in women taking Chloe® compared to COCs containing levonorgestrel, and similar for COCs containing desogestrel/gestodene/drospirenone. Patients with polycystic ovary syndrome have an increased risk of developing cardiovascular disease. Epidemiological studies have also shown an association between the use of hormonal contraceptives and an increased risk of arterial thromboembolism (myocardial infarction, transient ischemic attacks).

Thrombosis of other vessels, namely the veins and arteries of the liver, mesentery, kidney, brain or retina, has been extremely rarely reported in persons taking hormonal contraceptives.

The risk of VTE increases:

- with increasing age;

- if you smoke (with heavy smoking and with increasing age, the risk further increases, especially in women over 35 years of age. Women over 35 years of age should be strongly advised to stop smoking if they want to take Chloe®);

- with a burdened family history (i.e., if there is a history of cases of venous thromboembolism at a relatively young age in parents or close relatives). If a hereditary predisposition is suspected, a woman should consult a specialist before deciding on any hormonal contraception;

- with prolonged immobilization, surgical interventions on the lower extremities, neurosurgical operations or extensive trauma. In these situations, it is necessary to discontinue use (in the case of planned surgery, at least 4 weeks in advance), and not resume it until 2 weeks have passed after complete restoration of motor activity. If Chloe® has not been discontinued in advance, antithrombotic therapy should be considered;

- for obesity (BMI more than 30 kg/m2).

The risk of arterial thromboembolic complications or cerebrovascular accident increases:

- with increasing age;

- with dislipoproteinemia;

- for arterial hypertension;

- for migraine;

- for diseases of the heart valves;

- with atrial fibrillation;

Peripheral circulatory disorders may also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (namely, Crohn's disease or ulcerative colitis), and sickle cell anemia.

The increased risk of thromboembolism in the postpartum period must be taken into account.

An increase in the frequency or severity of migraine attacks while using Chloe® (which may be a harbinger of cerebrovascular accident) is grounds for immediate discontinuation of the drug.

There is no consensus regarding the potential role of varicose veins and superficial thrombophlebitis in the development of venous thromboembolism.

Biochemical factors that may indicate hereditary or acquired predisposition to venous or arterial thrombosis include activated protein C resistance (APC), hyperhomocysteinemia, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) .

When assessing the risk/benefit ratio, the physician should take into account that appropriate treatment of the underlying pathology may reduce the risk of thrombosis. Women taking Chloe® should be advised of the need to promptly report to their doctor if possible symptoms of thrombosis develop. In case of thrombosis or suspicion of its occurrence, treatment with Chloe® should be discontinued. Considering the teratogenicity of coagulants (coumarins), the use of adequate methods of contraception should be started.

Other states

In women with hypertriglyceridemia, while taking COCs (if there is a family history of this condition), there may be an increased risk of developing pancreatitis.

The relationship between taking COCs and arterial hypertension has not been established. If persistent arterial hypertension occurs, Chloe® should be discontinued and appropriate antihypertensive therapy should be prescribed. Taking the contraceptive can be continued if blood pressure normalizes.

If liver dysfunction occurs, temporary discontinuation of Chloe® may be necessary until laboratory parameters normalize. Recurrent cholestatic jaundice, which develops for the first time during pregnancy or previous use of sex hormones, requires discontinuation of COC use.

Women with a tendency to chloasma should avoid prolonged exposure to the sun and exposure to ultraviolet radiation while taking COCs.

While taking Chloe®, irregular bleeding (spotting or breakthrough bleeding) may sometimes occur, especially during the first months of therapy. Therefore, any irregular bleeding should be assessed only after an adaptation period of approximately 3 cycles.

If irregular bleeding recurs or develops after previous regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures should be taken to exclude malignancy (including diagnostic curettage of the uterine cavity) or pregnancy. In some cases, withdrawal bleeding may not develop during a break from taking the pills. If you do not take the pills regularly or in the absence of two menstrual-like bleeding in a row, pregnancy should be excluded before continuing to take the drug.

It is recommended to prescribe the drug after childbirth in the absence of breastfeeding only after the completion of the first normal menstrual cycle.

Treatment must be stopped 3 months before the planned pregnancy.

With diarrhea and vomiting, the contraceptive effect is reduced (without stopping the drug, it is necessary to use additional non-hormonal methods of contraception).

Tumors

There are reports of a slight increase in the risk of developing cervical cancer with long-term use of COCs. The connection with the use of COCs has not been proven. It remains controversial to what extent these findings are related to cervical pathology or to characteristics of sexual behavior (less frequent use of barrier methods of contraception). The most significant risk factor for developing cervical cancer is persistent human papillomavirus infection. A meta-analysis of 54 epidemiological studies showed that there is a slightly increased relative risk of developing breast cancer diagnosed in women currently taking COCs (relative risk 1.24). The increased risk gradually disappears within 10 years of stopping these drugs. Because breast cancer is rare in women under 40 years of age, the increase in breast cancer diagnoses in women who are currently or recently taking COCs is small relative to the overall risk of breast cancer. Its connection with the use of COCs has not been proven. The observed increased risk may also be a consequence of earlier diagnosis of breast cancer in women using COCs. Women who have ever used COCs are diagnosed with earlier stages of breast cancer than women who have never used them.

Laboratory tests

The use of COCs may affect the results of laboratory tests, including biochemical indicators of the efficiency of the liver, thyroid gland, adrenal glands and kidneys, the concentration of plasma proteins, for example, corticosteroid binding globulin, as well as the lipid/lipoprotein composition of the blood, indicators of carbohydrate metabolism and indicators of the blood coagulation system. However, deviations usually remain within the range of normal laboratory values.

Contraceptives Zentiva CHLOE - reviews

Mary
https://www.babyblog.ru/user/id1739735/313203

I took OK Chloe for 4 months. And everything would have been fine if the doctor had not prescribed clostilbegit, which I am well familiar with, from her friend. She didn’t prescribe any ultrasound, just drink and that’s it. As a result, I abandoned this doctor and changed gynecologist in January 2021. I switched to a paid but verified doctor by 4 friends and acquaintances. I stopped taking Ok according to her prescription. I learned from her that if I would continue...

Anonymous
https://v_dguk.ukr/ru/contraceptives_zentiva_khloe-r975290.html

I'm happy with the tablets. The skin is already 2 blisters and has improved significantly. Almost cleaned up.

If we compare the antiandrogenic effect of Chloe and others - Zhanine or Novinet - then it is much stronger.

My appetite has not increased. In 2 months I haven’t gained a single extra kg. There is no cellulite or stretch marks, as you can sometimes read in someone’s reviews. - Don’t blame your appetite and laziness on pills.

Libido increased in the first month. Then it returned to its previous normal. No depression or psychosis.)

Lately, small titmouses have begun to appear on the veins (- But the legs themselves do not hurt.

Headache - headaches become more frequent and blood pressure rises more often - which also affects the headache. Not very strong. I manage without pills, but still(

Menstruation is painless. started already on the 5th day of withdrawal. The doctor said it was normal.

Price-380-450 rub. Dzhierik Diana 35. - Absolutely similar and much cheaper.

Breasts have not increased.

I would like to say that if your doctor prescribed them to you, do not be afraid to take them. And your weight will not increase if you take care of yourself and your diet. and it no longer depends on the pills.

It's been a year since I started drinking them:

The weight has not increased. With my 170cm - 53kg.

The breasts have increased by only 3 cm..- And it has stayed that way all this year

My veins stopped hurting after I started taking more vitamin C.

The headaches have gone away and have not bothered me for a long time.

The acne has gone away, but the skin and hair are still oily.

Sex: libido has not decreased, but the problem is that a feeling of dryness has appeared;) well, you know what I mean….

Stretch marks:

There was a period when they suddenly appeared on the lower back after I started stretching and in the background there were just such adjustments and getting used to Chloe. Perhaps even my husband doesn’t notice them, but there are a couple and I know it.

Mood:

Perhaps the only change is tearfulness.. Once I burst into tears in the supermarket because the last jar of yogurt was taken away in front of me. -mmm yes, that’s already a diagnosis)))

However, my condition is not depressed at all, and even everything is fine, it’s just that at times my reaction is now too emotional

Due to the facts that have emerged, I am reducing the rating to 4! but no less)

Thinglision
https://otzyv.expert/podoshli-otlichno-i-bez-pobochek-983984

Advantages:

no side effects

Flaws:

a little expensive

Details:

Hello! I decided to start with a review about Chloe. Why? Yes, I’ve just been using it for a long time, I’ve studied this drug inside and out on myself.)) They were recommended to me by a regular gynecologist from our free clinic. She simply advised based on age, examination and I don’t know what yet, apparently it was an open secret.)) I bought these pills and started taking them in October 2012. Looking ahead, I will say that I have been taking them for 2 years, and everything is fine. There are only 28 tablets, of which 21 are active (yellow) and 7 are white (placebo). The whole trick here is to take them correctly and not miss the time of taking them, this is undesirable, you are setting up the body to work artificially, try to be more careful, strong pills. I take them at 21:00, after eating (an important point), with a small amount of water. During all this long time of taking it, I had no spotting, no nausea, no unwanted pregnancy. After a year of taking it I took a break and everything was fine, the cycle did not stop. When I started taking it in the second year, I was pleased with my breasts - my breasts grew for 2 months, then everything returned to normal. Objectively, I will say that these tablets turned out to be ideal for me; for those who are interested, in our city they cost 430 rubles.

uhtiiii
https://kupi-slona.com/catalog/kontraceptivy-zentiva-hloe/1299416

Chloe bought contraceptives as a generic version of the more expensive Diane-35 (twice as expensive). At first I started taking Lindinet-20, but it didn’t suit me. I felt very bad with it, and when I started taking Diane-35 I immediately realized that it was for me. Feeling...

Anastasia
https://lekotzyvy.com/review.php?id=4052

I've been on Chloe for three years now. The reason for such loyalty is simple - among all the OCs I tried, only this remedy did not cause problems with libido and weight. From other pills, even those that cost more than Chloe, my desire disappeared after a maximum of 3-4 months of taking it. And if there is no attraction, and there is no need to accept OK, the logic is simple. In terms of weight, I am even more pleased - during this time it fluctuated slightly, I added only 1.4 kg, while from other OCs I sometimes gained 9-10 kg in a year. I’m generally silent about the cosmetic effect, Chloe means healthy skin, thick hair, mandatory breast growth (due to the presence of an artificial analogue of female hormones) and the complete destruction of all unsightly protruding hairs on the body. I also undoubtedly like the fact that Chloe does not have such a strong side effect - it has not caused me any problems with veins or liver over the years. The most interesting thing is that the longer you take the drug, the fewer side effects there are, not vice versa. If in the first two months I had severe cycle interruptions, my mood alternately changed from excellent to disgusting and sometimes vomited without stopping, then by the middle of the third there was no trace of all this.

Advantages: Does not cause a decrease in libido or weight gain, effective, good cosmetic effect, does not harm the liver and veins

Disadvantages: At the beginning of use it caused cycle interruptions, mood changes, vomiting

Inna
https://www.piluli.ru/product/Khloe/review

Chloe drank for two years between pregnancies, she did not gain any excess weight, and she felt normal. There were pimples on my face and they still remained, but they didn’t help) After the cancellation, pregnancy occurred three months later, but for the last year of taking it, I took Lavita, special vitamins, along with contraceptives, so that there were no consequences and to increase the chances of conception.

Margarita
https://med-otzyv.ru/lekarstva/164-h/36123-hloe

Between my first and second births, Chloe drank for three years. Then she became pregnant without any problems. So I don't believe the horror stories about oral contraceptives. Is abortion better?!

Miller1995
https://otzovik.com/review_3125094.html

Advantages:

Release form, quality, convenience.

Flaws:

Not detected.

In fact, contraception is a delicate matter. What suits me won't suit everyone. Of course, you need to consult a doctor. It so happened that my mother is a doctor. Dermatologist-venereologist. And she has every right to write prescriptions. You can't buy Chloe without a prescription, although it makes no sense. But that’s not about that now. Tablets in convenient packaging. Twenty-one tablets with the necessary hormones, and another seven placebos with a sweetener. The tablets are very small, easy to swallow, smooth-coated, biconvex. I have never had any particular problems with acne, so I can’t say that it helps in the fight against acne. But the skin itself becomes better, looks healthier, and the tone evens out. They work great. It's not a big deal even if you missed one day of your appointment. The next day, just take two tablets and you will be happy. It alleviates pain during menstruation, but that’s for me personally. I don’t gain weight from these hormonal pills, but then again, that’s me. A friend of mine who also takes the same pills, quite the opposite - she gets plump. I know for sure that “Chloe” performs its function with “Hurray!” I have been using this drug for five years and have no plans to replace it. Didn't cause an allergic reaction.

Anonymous170627
https://otzovik.com/review_519341.html

Advantages:

Good contraception, slightly enlarged breasts, skin, hair in good condition, stable cycle, price

Flaws:

decreased libido, astringent discharge in the first month.

I've been taking it for about a year. In general, the drug is good, I didn’t notice anything terrible. I started taking it after Yarina as a cheaper drug and the doctor prescribed it. But at the moment I want to try Midiana, my gynecologist also advised me. I haven’t gained any weight, quite the opposite.

Nadi 01
https://irecommend.ru/content/ono-togo-stoilo-5

Of course, before starting this review, I must warn you that the choice of OCs is individual, and the doctor should select them based on your hormonal tests.

A year ago I thought about starting to take OK. The first reason was, of course, the need for contraception, and of course it was not without the wonderful cosmetological properties I had heard, which I also needed because... my face, covered with acne, looked very much like a field after a bombing